XML 11 R1.htm IDEA: XBRL DOCUMENT v3.21.1
Document And Entity Information - USD ($)
 12 Months Ended
Dec. 31, 2020
Apr. 20, 2021
Jun. 30, 2020
Document Information [Line Items]      
Entity Central Index Key 0000898437    
Entity Registrant Name Anika Therapeutics, Inc.    
Amendment Flag true    
Current Fiscal Year End Date --12-31    
Document Fiscal Period Focus FY    
Document Fiscal Year Focus 2020    
Document Type 10-K/A    
Document Annual Report true    
Document Period End Date Dec. 31, 2020    
Document Transition Report false    
Entity File Number 001-14027    
Entity Incorporation, State or Country Code DE    
Entity Tax Identification Number 04-3145961    
Entity Address, Address Line One 32 Wiggins Avenue    
Entity Address, City or Town Bedford    
Entity Address, State or Province MA    
Entity Address, Postal Zip Code 01730    
City Area Code 781    
Local Phone Number 457-9000    
Title of 12(b) Security Common Stock, par value $0.01 per share    
Trading Symbol ANIK    
Security Exchange Name NASDAQ    
Entity Well-known Seasoned Issuer No    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Accelerated Filer    
Entity Small Business false    
Entity Emerging Growth Company false    
Entity Shell Company false    
Entity Public Float     $ 530,765,794
Entity Common Stock, Shares Outstanding   14,366,686  
Amendment Description This Amendment No. 1 on Form 10-K/A (this “Amendment”) to the Annual Report on Form 10-K of Anika Therapeutics, Inc. for the fiscal year ended December 31, 2020, initially filed with the Securities and Exchange Commission (the “SEC”) on March 5, 2021 (the “Original Filing”), is being filed principally to correct typographical errors that resulted during the creation of the EDGAR version of the Original Filing. As the result of these errors, the Original Filing failed to include the following, all of which are included in this Amendment:     ● The entire paragraph, except for the word “Research”, in the section captioned “Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations – Results of Operations – Year ended December 31, 2020 compared to year ended December 31, 2019 – Statement of Operations Detail – Research and development.”   ● The words “a per share and tax effected basis.” at the end of the first paragraph in the section captioned “Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations – Results of Operations – Non-GAAP Financial Measures – Adjusted Net Income (Loss) and Adjusted EPS.”   ● The words “To the Board of Directors and Stockholders of Anika Therapeutics, Inc.” in the beginning of the “Report of Independent Registered Public Accounting Firm” contained within the section captioned “Item 8. Financial Statements and Supplementary Data.”   ● The conformed signature of Deloitte & Touche LLP on the “Report of Independent Registered Public Accounting Firm” contained within the section captioned “Item 9A. Controls and Procedures.” The Company received the manually signed Internal Control Report from Deloitte & Touche prior to filing the Original Filing.   In addition, this Amendment is being filed to update the explanation surrounding employees added in 2020 in the third sentence of the third full paragraph of the section captioned “Item 1. Business – Human Capital Management.”   This Amendment amends the cover page and includes Items 1, 7, 8, and 9A in their entirety without change from the Original Filing except as described above. In addition, pursuant to Rule 12b-15 under the Securities Exchange Act of 1934, we are including with this Amendment new certifications of our principal executive officer and principal financial officer pursuant to Sections 302 and 906 of the Sarbanes-Oxley Act of 2002. Accordingly, Item 15 of Part IV has also been amended to reflect the filing of these new certifications.   Except for the foregoing amended information, this Amendment does not amend or update any other information contained in the Original Filing. This Amendment does not reflect events occurring after the date of the filing of the Original Filing or modify or update those disclosures that may be affected by subsequent events. Accordingly, this Amendment should be read in conjunction with the Original Filing and with our other filings with the SEC.